Chargement en cours...
P01.041 Secondary prophylaxis with romiplostim for temozolomide-induced thrombocytopenia in newly diagnosed glioblastoma
BACKGROUND: Thrombocytopenia is a major adverse event of temozolomide (TMZ) chemotherapy. It may lead to dose reduction/interruption or bleeding. Platum (NCT02227576) was a phase II open label, multicenter single arm trial evaluating the thrombopoetin receptor agonist, romiplostim, for secondary pre...
Enregistré dans:
| Publié dans: | Neuro Oncol |
|---|---|
| Auteurs principaux: | , , , , , , , , |
| Format: | Artigo |
| Langue: | Inglês |
| Publié: |
Oxford University Press
2018
|
| Sujets: | |
| Accès en ligne: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6144386/ https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/noy139.083 |
| Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|